{"url_path":"/sec/bblg/8-k/2026-07-09/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-032694-index.html","accession_number":"0001493152-26-032694","cik":"0001419554","ticker":"BBLG","issuer_name":"Bone Biologics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1419554/0001493152-26-032694-index.html","primary_entity_key":"0001419554","primary_entity_name":"Bone Biologics Corp"},"word_count":163,"has_tables":true,"body_markdown":"**Item 9.01****Financial\nStatements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n4.1\n \n[Form of Series F Warrant dated July 9, 2026](ex4-1.htm)\n\n4.2\n \n[Form of Series G Warrant dated July 9, 2026](ex4-2.htm)\n\n4.3\n \n[Form of Pre-Funded Warrant dated July 9, 2026](ex4-3.htm)\n\n4.4\n \n[Form of Placement Agent Warrant dated July 9, 2026](ex4-4.htm)\n\n10.1*\n \n[Form of Securities Purchase Agreement dated July 7, 2026](ex10-1.htm)\n\n10.2\n \n[Form of Registration Rights Agreement dated July 7, 2026](ex10-2.htm)\n\n99.1\n \n[Press release dated July 7, 2026](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n \n \n\n*\n \nCertain\ninformation has been omitted from this exhibit in reliance upon Item 601(a)(5) of Regulation S-K and will be furnished to the Securities\nand Exchange Commission upon request.\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**BONE BIOLOGICS CORPORATION**\n\n \n \n\nDate:\nJuly 9, 2026\n \n \n\n \nBy:\n*/s/\nJeffrey Frelick*\n\n \n \nJeffrey\nFrelick\n\n \n \nChief\nExecutive Officer"}